Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LLY
  • CUSIP: 53245710
  • Web: www.lilly.com
Capitalization:
  • Market Cap: $92.38399 billion
  • Outstanding Shares: 1,055,000,000
Average Prices:
  • 50 Day Moving Avg: $80.84
  • 200 Day Moving Avg: $82.02
  • 52 Week Range: $64.18 - $86.72
P/E:
  • Trailing P/E Ratio: 36.31
  • Foreward P/E Ratio: 18.36
  • P/E Growth: 1.76
Sales & Book Value:
  • Annual Revenue: $22 billion
  • Price / Sales: 4.02
  • Book Value: $13.37 per share
  • Price / Book: 6.28
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.5%
Profitability:
  • EBIDTA: $5.99 billion
  • Net Margins: 11.12%
  • Return on Equity: 28.71%
  • Return on Assets: 10.74%
Debt:
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 1.39%
  • Quick Ratio: 1.01%
Misc:
  • Average Volume: 3.48 million shs.
  • Beta: 0.34
  • Short Ratio: 2.62
 

Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings data on Tuesday, July, 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. The business earned $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and Company had a net margin of 11.12% and a return on equity of 28.71%. The company's revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $0.86 EPS. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

18 analysts have issued 1 year price targets for Eli Lilly and Company's stock. Their predictions range from $71.00 to $105.00. On average, they expect Eli Lilly and Company's share price to reach $89.18 in the next twelve months. View Analyst Ratings for Eli Lilly and Company.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and Company's key competitors?

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
  • Michael J. Harrington, Senior Vice President, General Counsel
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.76%), Vanguard Group Inc. (6.65%), BlackRock Inc. (6.03%), State Street Corp (3.98%), Franklin Resources Inc. (2.66%) and State Farm Mutual Automobile Insurance Co. (1.89%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Winslow Capital Management LLC, Franklin Resources Inc., Bank of New York Mellon Corp, FMR LLC, American Century Companies Inc., UBS Asset Management Americas Inc. and Capital Guardian Trust Co.. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dodge & Cox, Renaissance Technologies LLC, Harbour Capital Advisors LLC, Vanguard Group Inc., AJO LP, Westfield Capital Management Co. LP and BlackRock Inc.. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $83.91.


MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  693 (Vote Outperform)
Underperform Votes:  515 (Vote Underperform)
Total Votes:  1,208
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $89.18 (6.28% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Morgan StanleyReiterated RatingHold$86.00LowView Rating Details
9/11/2017Jefferies Group LLCReiterated RatingBuy$89.00 -> $89.00LowView Rating Details
9/8/2017Piper Jaffray CompaniesReiterated RatingOverweight$103.00 -> $105.00LowView Rating Details
9/6/2017BMO Capital MarketsReiterated RatingUnderperform$73.00 -> $71.00LowView Rating Details
8/31/2017Leerink SwannReiterated RatingHoldLowView Rating Details
8/4/2017Berenberg BankReiterated RatingBuy$98.00LowView Rating Details
7/26/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/4/2017Citigroup Inc.Reiterated RatingBuy$100.00LowView Rating Details
7/4/2017Barclays PLCBoost Price TargetOverweight$85.00 -> $90.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy -> Buy$92.00HighView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
4/19/2017Credit Suisse GroupReiterated RatingOutperform$87.00LowView Rating Details
4/17/2017Cowen and CompanyBoost Price TargetOutperform$85.00 -> $95.00MediumView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015Bank of America CorporationReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Eli Lilly and Company (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$1.03N/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.60 billion$5.82 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.10
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.04$1.06$1.05
Q3 20172$1.03$1.06$1.05
Q4 20172$1.01$1.04$1.03
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Most Recent Dividend:9/8/2017
Annual Dividend:$2.08
Dividend Yield:2.48%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:90.04% (Trailing 12 Months of Earnings)
50.12% (Based on This Year's Estimates)
45.51% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.72%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
Source:
DateHeadline
prnewswire.com logoGeisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for ... - PR Newswire (press release)
www.prnewswire.com - September 25 at 7:04 PM
finance.yahoo.com logoGeisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death
finance.yahoo.com - September 25 at 8:33 AM
finance.yahoo.com logoColorectal Cancer Market: Global Industry Analysis Trends, Share, Growth Drivers, Outlook and 2025 Forecasts Research Report
finance.yahoo.com - September 22 at 11:51 AM
prnewswire.com logoDrug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune Pharma, Eli Lilly, and Merck
www.prnewswire.com - September 22 at 11:51 AM
businesswire.com logoGlobal Animal Health Market: Industry Analysis & Outlook 2017-2021 - Research and Markets
www.businesswire.com - September 21 at 3:49 PM
prnewswire.com logoRecombinant DNA Technology Market Analysis By Product, By Component, By Application, By End-use And Segment Forecasts, 2014 - 2025
www.prnewswire.com - September 21 at 3:49 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Major Shareholder Sells $15,680,700.00 in Stock
www.americanbankingnews.com - September 18 at 4:16 PM
americanbankingnews.com logoFY2017 EPS Estimates for Eli Lilly and Company Raised by Analyst (LLY)
www.americanbankingnews.com - September 18 at 2:56 AM
reuters.com logoLilly/Incyte pill beats placebo in mid-stage eczema trial - Reuters - Reuters
www.reuters.com - September 17 at 12:44 AM
finance.yahoo.com logoLilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
finance.yahoo.com - September 16 at 6:04 AM
finance.yahoo.com logoEli Lilly Still Looking for Lower Prices
finance.yahoo.com - September 16 at 6:04 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - September 15 at 5:32 PM
streetinsider.com logoEli Lilly & Co. (LLY) & Incyte Corp. (INCY) Announces Baricitinib Meets Primary Endpoint in Phase 2 Study
www.streetinsider.com - September 15 at 6:06 AM
finance.yahoo.com logoEli Lilly Partnering Deals and Alliances 2010 to 2017
finance.yahoo.com - September 15 at 6:06 AM
finance.yahoo.com logoEli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2017 (record date) : By the numbers : September 14, 2017
finance.yahoo.com - September 15 at 6:06 AM
americanbankingnews.com logoEli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.50 Billion
www.americanbankingnews.com - September 15 at 5:20 AM
finance.yahoo.com logoJardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
finance.yahoo.com - September 14 at 7:16 AM
finance.yahoo.com logoEli Lilly & Co. – Value Analysis (NYSE:LLY) : September 12, 2017
finance.yahoo.com - September 14 at 7:16 AM
finance.yahoo.com logoIs Lilly Headed for the Valley?
finance.yahoo.com - September 14 at 7:16 AM
americanbankingnews.com logoZacks: Analysts Anticipate Eli Lilly and Company (LLY) to Announce $1.03 EPS
www.americanbankingnews.com - September 14 at 12:24 AM
seekingalpha.com logoLilly Cuts Back Again - Seeking Alpha
seekingalpha.com - September 13 at 5:53 AM
streetinsider.com logoEli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study
www.streetinsider.com - September 12 at 3:41 AM
finance.yahoo.com logoLilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
finance.yahoo.com - September 12 at 3:41 AM
finance.yahoo.com logoEli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : September 11, 2017
finance.yahoo.com - September 12 at 3:41 AM
streetinsider.com logoEli Lilly & Co. (LLY) Presents Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data ... - StreetInsider.com
www.streetinsider.com - September 11 at 10:38 PM
streetinsider.com logoEli Lilly & Co. (LLY) to Present New Data for Olumiant and Taltz at EADV - StreetInsider.com
www.streetinsider.com - September 11 at 10:38 PM
streetinsider.com logoEli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study - StreetInsider.com
www.streetinsider.com - September 11 at 10:38 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - September 11 at 5:46 PM
finance.yahoo.com logoLilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - September 10 at 6:00 AM
finance.yahoo.com logoLilly Breast Cancer Drug Results May Challenge Pfizer Pill
finance.yahoo.com - September 10 at 12:57 AM
wsj.com logoEli Lilly to Cut 8% of Jobs, Invest More on New Drugs
www.wsj.com - September 9 at 7:55 PM
finance.yahoo.com logoIHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine
finance.yahoo.com - September 9 at 7:55 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Earns "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 11:58 AM
rttnews.com logoEli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study
www.rttnews.com - September 9 at 5:18 AM
msn.com logoEli Lilly To Cut 8 Percent Of Jobs
www.msn.com - September 9 at 5:18 AM
247wallst.com logoEli Lilly Hopes to Benefit From Joining the Layoff Brigade — 3,500 Pink Slips!
247wallst.com - September 9 at 5:18 AM
bloomberg.com logoDrugmaker Eli Lilly Will Cut 3,500 Jobs
www.bloomberg.com - September 9 at 5:18 AM
finance.yahoo.com logoHurricane Irma Bears Down on Equities and Disney Slide Hits Dow
finance.yahoo.com - September 9 at 5:17 AM
finance.yahoo.com logoIHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
finance.yahoo.com - September 9 at 5:17 AM
finance.yahoo.com logoEli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective
finance.yahoo.com - September 9 at 5:17 AM
finance.yahoo.com logoUnderstanding Merck’s Valuation after 2Q17
finance.yahoo.com - September 9 at 5:17 AM
finance.yahoo.com logoPharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018
finance.yahoo.com - September 9 at 5:17 AM
abcnews.go.com logoDrugmaker Lilly to trim workforce by nearly 9 percent
abcnews.go.com - September 8 at 6:23 AM
americanbankingnews.com logoSunTrust Banks Equities Analysts Raise Earnings Estimates for Eli Lilly and Company (LLY)
www.americanbankingnews.com - September 8 at 6:00 AM
reuters.com logoLilly to cut 8 percent of jobs in bid to cut costs - Reuters
www.reuters.com - September 8 at 1:33 AM
usatoday.com logoEli Lilly: 3,500 job cuts to make firm stronger, CEO says - USA Today - USA TODAY
www.usatoday.com - September 8 at 1:33 AM
finance.yahoo.com logoPRESS DIGEST - Wall Street Journal - Sept 8
finance.yahoo.com - September 8 at 1:33 AM
finance.yahoo.com logo[$$] Eli Lilly to Cut 8% of Jobs, Invest More on New Drugs
finance.yahoo.com - September 8 at 1:33 AM
americanbankingnews.com logoAnalyzing GlaxoSmithKline PLC (GSK) and Eli Lilly and (LLY)
www.americanbankingnews.com - September 7 at 12:50 PM
investorplace.com logoEli Lilly and Co (LLY) Layoffs: Drugmaker to Cut 3,500 Jobs
investorplace.com - September 7 at 12:29 PM

Social

Chart

Eli Lilly and Company (LLY) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff